Boehringer Ingelheim licenses Vectron Biosolutions’ expression technology platform

Back to Newslist September 01 | 2015

Ingelheim, Germany, and Trondheim, Norway - Boehringer Ingelheim, a research-based, global pharmaceutical company, announced today the licensing of Vectron Biosolutions’ expression technology platform.

This non-exclusive license agreement comes as a result of a successful joint feasibility study between the two companies in which Vectron’s proprietary genetic elements were tested for high-yield, soluble production of a protein of interest to Boehringer Ingelheim in Escherichia coli. This agreement gives Boehringer Ingelheim the right to use Vectron’s technology for both production of biopharmaceutical products from their own in-house pipeline, and as part of the Boehringer Ingelheim BioXcellence™ offerings in contract manufacturing.

”We at Boehringer Ingelheim are permanently developing and scouting novel and innovative technologies to further improve our strong microbial production platform. We believe that there is a high synergy of the Vectron Biosolutions’ technology with Boehringer Ingelheim’s own proprietary E. coli based expression systems”, said Dr. Jan Schöning, Head of Global Technology and Innovation Management Biopharmaceuticals at Boehringer Ingelheim.

“We are pleased that our technology’s potential is being recognized by one of the leading pharmaceutical companies. With Boehringer Ingelheim’s strong position in the industry, we anticipate that many future biopharmaceutical proteins will be produced using our technology“, said Dr. Trond Erik Vee Aune, CEO at Vectron Biosolutions.

About Boehringer Ingelheim

The Boehringer Ingelheim group is one of the world’s 20 leading pharmaceutical companies. Headquartered in Ingelheim, Germany, Boehringer Ingelheim operates globally with 146 affiliates and a total of more than 47,700 employees. The focus of the family-owned company, founded in 1885, is researching, developing, manufacturing and marketing new medications of high therapeutic value for human and veterinary medicine. In 2014, Boehringer Ingelheim achieved net sales of about 13.3 billion euros. R&D expenditure corresponds to 19.9 per cent of its net sales.

For more information, please visit www.boehringer-ingelheim.com
Twitter: www.twitter.com/boehringer 

As a leading biopharmaceutical contract manufacturer with more than 35 years of experience – the company has brought more than 20 biologic medicines to patients around the world. Boehringer Ingelheim Biopharma Contract Manufacturing is represented by its brand Boehringer Ingelheim BioXcellence™. Boehringer Ingelheim BioXcellence™ offers tailor-made contract development and manufacturing services to the biopharmaceutical industry, providing the entire production technology chain from DNA to fill and finish under one brand at its facilities in Biberach (Germany), Vienna (Austria), Fremont (USA) and Shanghai (China). Boehringer Ingelheim BioXcellence™ can secure product supply  throughout the entire product lifecycle—transferring customer projects at any stage, delivering to almost any scale and thereby makes outsourcing easy.

Boehringer Ingelheim RCV GmbH & Co KG, located in Vienna, Austria, is Boehringer Ingelheim’s center of excellence for Biopharmaceutical development and production in microbial systems.

More information:  www.bioxcellence.com

About Vectron Biosolutions

Vectron Biosolutions was founded in 2008 based on the expression vector technology developed in Professor Svein Valla’s research group at the Norwegian University of Science and Technology, in Trondheim, Norway. The company offers research and development services using its proprietary expression technology platform that has been developed for production of proteins in E. coli and other bacteria. This modular technology is comprised of vector backbones and genetic libraries of Pm promoters, xylS transcription regulators, 5’-UTRs, and signal peptides. Using combinations of these elements it is possible to design expression vectors that are optimized for high-yield, soluble expression of numerous proteins in E. coli and in other bacteria. Vectron Biosolutions is a privately owned company.

More information: www.vectronbiosolutions.com

Media contact Boehringer Ingelheim:

Boehringer Ingelheim GmbH
Binger Str. 173
55216 Ingelheim
Germany

Dr. Ralph Warsinsky
Phone +49 6132 77 70 51
mailto: Ralph.Warsinsky@boehringer-ingelheim.com

Contact Vectron Biosolutions:

Click here

Links

Read the press release